ストックスクリーナーアプリを入手
2.45
6.99%
0.16
前日終値:
$2.29
開ける：
$2.5
24時間の取引高:
1.67M
Relative Volume:
4.64
時価総額：
$106.98M
収益：
$3.91M
当期純損益:
$-206.53M
株価収益率:
-0.9869
EPS:
-2.4825
ネットキャッシュフロー:
$-167.78M
1週間 パフォーマンス:
+87.02%
1か月 パフォーマンス:
+174.94%
6か月 パフォーマンス:
+140.20%
1年 パフォーマンス:
+31.02%
1日の値動き範囲:
$2.31
$2.70
1週間の範囲:
$1.20
$2.70
52週間の値動き範囲:
$0.595
$2.70
I Mab Adr Stock (IMAB) Company Profile
IMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
2.45 | 106.98M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-09 | 開始されました | Siebert Williams Shank | Buy |
| 2021-06-02 | 開始されました | Daiwa Securities | Buy |
| 2021-03-15 | 開始されました | Needham | Buy |
| 2021-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-25 | 開始されました | Piper Sandler | Overweight |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 開始されました | China Renaissance | Buy |
| 2020-02-11 | 開始されました | Jefferies | Buy |
すべてを表示
I Mab Adr (IMAB) 最新ニュース
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance
Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance
I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa
I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com
Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
Use of failure mode and effect analysis to improve the monoclonal antibody drugs management process in pharmacy intravenous admixture services - Nature
I-Mab Chairman plans $2 million ADS purchase - Investing.com India
I-Mab’s Third Quarter Results: Progress in Cancer Immunotherapies - TipRanks
I-Mab names Sean Fu as new CEO - Investing.com
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature
I-Mab: Dropping Coverage - Morningstar
I-Mab Full-Year Update Uneventful; Potential Catalysts in H2 2023 - Morningstar
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
Results for A amyloid PET SUVr and B Centiloid scale assessments from study 201 core - ResearchGate
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - HK.Morningstar.com
Fig. 3 A Scatchard analysis of 125 I-trastuzumab binding to human... - ResearchGate
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Markets Brief: Stocks Fall for the First Time in a Month, More Retail Earnings Ahead - Morningstar
Sabah does not deserve this, MAB! - Daily Express Malaysia
Fig. 2 Flowchart of Sicilian adverse drug reaction (ADR) report... - ResearchGate
Markets Brief: How High Can Mortgage Rates Go? - Morningstar
New 5-Star Stocks - Morningstar
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database - Frontiers
I Mab Adr (IMAB) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):